Consumer medicine information

Soolantra Cream

Ivermectin

BRAND INFORMATION

Brand name

Soolantra

Active ingredient

Ivermectin

Schedule

S4

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using Soolantra Cream.

What is in this leaflet

This leaflet answers some common questions about SOOLANTRA.

It does not contain all the available information. It does not use the place of talking to your doctor or pharmacist.

All medicines have risks and benefits. Your doctor has weighed the risks of you using SOOLANTRA against the benefits they expect it will have for you.

If you have any concerns about this medicine, ask your doctor or pharmacist.

Keep this leaflet with your medicine. You may need to read it again.

What SOOLANTRA is used for

SOOLANTRA contains the active substance ivermectin that belongs to a group of medicines called avermectins.

SOOLANTRA is used to treat pimples and spots found with rosacea.

Your doctor, however may prescribe it for another purpose.

Ask your doctor if you have any questions about why SOOLANTRA has been prescribed for you.

This medicine is available only with a doctor’s prescription.

SOOLANTRA is not addictive.

Before you use SOOLANTRA

When you must not use it

Do not use SOOLANTRA:

  • if you have an allergy to any medicine containing ivermectin
  • if you have an allergy to any of the ingredients listed at the end of this leaflet
  • for any children under 18 years of age

Some of the symptoms of an allergic reaction may include:

  • shortness of breath
  • wheezing or difficulty breathing
  • swelling of the face, lips, tongue or other parts of the body
  • rash, itching or hives of the skin

Do not use SOOLANTRA after the use by (expiry) date printed on the pack or if the packaging is torn or shows signs of tampering. If it has expired or is damaged, return it to your pharmacist for disposal.

Before you start to use it

Tell your doctor if you have allergies to any other medicines, foods, preservatives or dyes.

SOOLANTRA contains cetyl alcohol and stearyl alcohol which may cause local skin reactions (e.g. contact dermatitis), methyl hydroxybenzoate (E218) and propyl hydroxybenzoate (E217) which may cause allergic reactions (possibly delayed), and propylene glycol which may cause skin irritation.

Tell your doctor if you have or have had any of the following medical conditions:

  • Kidney disease
  • Liver disease

Tell your doctor if you are pregnant or plan to become pregnant or are breast-feeding. Your doctor can discuss with you the risks and benefits involved.

If you have not told your doctor about any of the above, tell him/her before you start taking SOOLANTRA.

SOOLANTRA should only be used on the skin of the face. At the start of the treatment, some patients may experience worsening of the symptoms of rosacea, however this is uncommon and usually resolves within 1 week of the treatment. Talk to your doctor if this happens.

SOOLANTRA should not be used on the following areas:

  • eyes or eyelids
  • mouth
  • lips

If SOOLANTRA comes into contact with these areas, the area should be rinsed immediately with plenty of water.

SOOLANTRA is not recommended for use in children under 18 years.

Using other medicines

Tell your doctor or pharmacist if you are taking any other medicines, including any that you get without a prescription from your pharmacy, supermarket or health food shop. Your doctor and pharmacist have more information on medicines to be careful with or avoid while taking this medicine.

How to use SOOLANTRA

How much to use

Five small pea size amounts of SOOLANTRA is the daily recommended dose (approximately 1 gram).

Ask your doctor or pharmacist if you are not sure how much to apply. They will tell you exactly how much to use for each application.

Follow the instructions they give you.

How to use it

SOOLANTRA is only intended for use on the skin of the face.

It is recommended that SOOLANTRA be applied once per day after your usual cleansing routine, and before any cosmetics or sunscreens are applied.

Apply a small, pea size amount of SOOLANTRA to each of the following five areas of the face: forehead, chin, nose, and to each cheek, avoiding the eyes, eyelids, lips and mouth. The product should be applied smoothly and evenly as a thin layer across your face.

Hands should be washed after applying SOOLANTRA.

After applying SOOLANTRA use a non-comedogenic, broad spectrum, SPF 50+ sunscreen and wear protective clothing to protect your skin from UV rays.

Cosmetics can also be applied after SOOLANTRA has dried.

How to open the tube with a child-resistant cap.

To avoid spillage, do not squeeze the tube while opening or closing. Push down on the cap and turn in a counter clockwise (to the left) a quarter of a turn.

  1. Push down the cap

  1. twist in the direction of the arrow as shown below (counterclockwise).

How to close the tube with a child-resistant cap.

Gently press down on the child resistant cap and twist to the right (clockwise).

How long to use it

Your doctor or pharmacist will tell you how long to use SOOLANTRA.

Continue using your medicine for as long as your doctor tells you. You should use SOOLANTRA daily over the treatment course. The doctor may decide that the treatment course should be repeated. The duration of treatment can vary from person to person and depends on the severity of your skin condition.

Pimples and spots will be reduced only after several applications of this medicine. It is important that you continue using SOOLANTRA as long as prescribed by your doctor.

If you are not sure how long to use SOOLANTRA, talk to your doctor or pharmacist.

If you forget to use it

If it is almost time for your next dose, skip the dose you missed and use your next dose when you are meant to.

Do not use a double dose to make up for the dose that you missed.

If you have trouble remembering to use your medicine, ask your pharmacist for some hints.

If you swallow it

Immediately telephone your doctor, or Poisons Information Centre (telephone 13 11 26), or go to Accident and Emergency at your nearest hospital, if you think you or anyone else may have taken too much SOOLANTRA.

Do this even if there are no signs of discomfort or poisoning. You may need urgent medical attention.

While you are using SOOLANTRA

Things you must do

Tell all doctors and pharmacists who are treating you that you are using SOOLANTRA.

If you feel that SOOLANTRA is not helping your condition, tell your doctor or pharmacist.

Tell your doctor if, for any reason, you have not used SOOLANTRA exactly as prescribed. Otherwise, your doctor may think that it was not effective and change your treatment unnecessarily.

If you become pregnant while using SOOLANTRA, tell your doctor.

Things you must not do

Do not use SOOLANTRA under dressings or on large areas of skin unless your doctor tells you.

Do not use SOOLANTRA in or near the eyes.

Do not give SOOLANTRA to anyone else, even if they have the same symptoms as yours.

Do not use SOOLANTRA to treat other complaints unless your doctor or pharmacist tells you to.

Things to be careful of

Avoid contact with the eyes, eyelids, lips and mouth. If SOOLANTRA comes into contact with these areas, the area should be rinsed immediately with plenty of water.

Ask your doctor or pharmacist if you are concerned about the length of time you have been using SOOLANTRA.

Side effects

All medicines may have some unwanted side effects. Sometimes they are serious, but most of the time they are not. Your doctor has weighed the risks of using this medicine against the benefits they expect it will have for you.

Do not be alarmed by this list of possible side effects. You may not experience any of them.

Tell your doctor if you notice any of the following and they worry you:

  • skin burning sensation
  • skin irritation
  • itching of the skin
  • dry skin
  • redness
  • Rosacea aggravation
  • Swelling of the face

These are mild side effects of the medicine and are usually mild and short-lived.

If any of the following happen, stop using SOOLANTRA and tell your doctor immediately, or go to Accident and Emergency at your nearest hospital:

  • shortness of breath
  • wheezing or difficulty breathing
  • swelling of the face, lips, tongue or other parts of the body
  • rash, itching or hives of the skin
  • Liver enzyme elevations (ALAT/ASAT)

These are very serious side effects. If you have them, you may have had a serious allergic reaction to SOOLANTRA. You may need urgent medical attention or hospitalisation. Serious side effects are very rare.

Tell your doctor if you notice anything else that is making you feel unwell. Other side effects not listed above may occur in some patients.

Do not be alarmed by this list of possible side effects. You may not experience any of them.

After using SOOLANTRA

If you have queries about any aspect of your medicine, or any questions regarding the information in this leaflet, discuss them with your doctor or pharmacist.

Storage

Keep the medicine in a cool dry place where the temperature stays below 30°C. Do not freeze.

Do not store it, or any other medicine, in a bathroom, near a sink, or on a window-sill.

Do not leave it in the car. Heat and dampness can destroy some medicines.

Keep it where children cannot reach it. A locked cupboard at least one-and-a-half metres above the ground is a good place to store medicines.

Disposal

If your doctor tells you to stop using SOOLANTRA or it has passed its expiry date, ask your pharmacist what to do with any that is left over.

Return any unused medicine to your pharmacist.

Product description

What it looks like

SOOLANTRA is a white to light yellow cream. It is supplied in plastic tube with a plastic cap containing 2 g, 15 g, 30 g, 45 g or 60 g of cream. For tube sizes greater than 2 g, the cap is a childresistant closure.

Not all pack sizes may be available.

Ingredients

Each gram of SOOLANTRA contains 10 mg (or 1.0% w/w) of ivermectin as the active ingredient.

Inactive ingredients:

  • glycerol
  • isopropyl palmitate
  • carbomer copolymer (type B)
  • dimethicone 20
  • disodium edetate
  • citric acid monohydrate
  • cetyl alcohol
  • stearyl alcohol
  • ceteareth-20
  • sorbitan stearate
  • methyl hydroxybenzoate (E218)
  • propyl hydroxybenzoate (E217)
  • phenoxyethanol
  • propylene glycol
  • oleyl alcohol
  • sodium hydroxide
  • purified water.

Sponsor

Galderma Australia Pty Ltd
Suite 4, 13B Narabang Way
Belrose NSW 2085
Ph 1800 800 765

Distributed in New Zealand by:

Healthcare Logistics
58 Richard Pearse Drive
Airport Oaks
Auckland
Ph: 0800 174 104

Made in France

Australian Registration Number: AUST R 227125

® Registered Trademark

This leaflet was updated on 11 March 2020.

Published by MIMS May 2020

BRAND INFORMATION

Brand name

Soolantra

Active ingredient

Ivermectin

Schedule

S4

 

1 Name of Medicine

Ivermectin.

2 Qualitative and Quantitative Composition

One gram of Soolantra cream contains 10 mg (or 1.0% w/w) of ivermectin.
Excipients with known effect. Methyl hydroxybenzoate, propyl hydroxybenzoate.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Soolantra is a white to pale yellow hydrophilic cream.

4 Clinical Particulars

4.9 Overdose

There are no reports of overdosage with Soolantra.
In accidental or significant exposure to unknown quantities of veterinary formulations of ivermectin in humans, either by ingestion, inhalation, injection, or exposure to body surfaces, the following adverse effects have been reported most frequently: rash, oedema, headache, dizziness, asthenia, nausea, vomiting, and diarrhoea. Other adverse effects that have been reported include: seizure, ataxia, dyspnea, abdominal pain, paresthesia, urticaria, and contact dermatitis.
In case of accidental ingestion, supportive therapy, if indicated, should include parenteral fluids and electrolytes, respiratory support (oxygen and mechanical ventilation if necessary) and pressor agents if clinically significant hypotension is present. Induction of emesis and/or gastric lavage as soon as possible, followed by purgatives and other routine antipoison measures, may be indicated if needed to prevent absorption of ingested material.
For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

5 Pharmacological Properties

5.3 Preclinical Safety Data

Genotoxicity. Ivermectin was not mutagenic in vitro in bacterial and photobacterial reverse mutation assays, in the mouse lymphoma assay, in the photochromosomal aberration assay in Chinese hamster ovary cells, and in vivo in the oral micronucleus test in rats.
Carcinogenicity. Chronic (1 year) repeated topical application of Soolantra enhanced simulated solar ultraviolet radiation induced nonmelanoma skin carcinogenesis in albino Skh HR-1 hairless mouse (tumour potency factor in both sexes combined was 1.69; and 1.74 in male mice and 1.51 in female mice; compared with an expected no adverse effect tumour potency factor of 1.00). The albino Skh HR-1 hairless mouse is more sensitive to ultraviolet radiation induced carcinogenesis than humans. Accordingly the clinical relevance of these findings is uncertain. However repeated unprotected exposure of Soolantra treated skin to ultraviolet radiation sources (including sunlight) should be avoided (see Section 4.4 Special Warnings and Precautions for Use).
In a 2 year topical carcinogenicity study in mice (without simulated solar light exposure), Soolantra was not tumorigenic when applied daily at doses corresponding to up to 10 mg/kg/day of ivermectin. At this dose, the plasma AUC in mice was 645.54 (m)/352 (f) times the human plasma AUC associated with the maximum recommended topical use of Soolantra.
In a 2 year oral carcinogenicity study in rats, ivermectin was considered not tumorigenic when administered daily at doses up to 3 mg/kg/day. At this dose, the plasma exposure of animals represented at least 282 times the human plasma AUC associated with the maximum recommended topical use of Soolantra.
At the oral dose of 9 mg/kg/day (corresponding to 832 (m)/924 (f) times the human plasma AUC associated with the maximum recommended topical use of Soolantra), an increase in the incidence of benign hepatocellular adenomas and related hepatic preneoplastic changes were reported in males only. There was also a higher incidence of pancreatic benign islet cell adenomas in males, and islet cell carcinoma with no evidence of distant metastasis in females. These neoplastic changes in rodents are not currently considered to be relevant to humans.

6 Pharmaceutical Particulars

6.7 Physicochemical Properties

Ivermectin contains a minimum of 90% of 22, 23-dihydroavermectin B1a (where the R group is ethyl) and a maximum of 10% of 22, 23-dihydroavermectin B1b (the R group is methyl).
Ivermectin is a white or yellowish white crystalline powder. It is freely soluble in methylene chloride, soluble in ethanol (96%) and practically insoluble in water. It presents a specific optical rotation between -20 to -17 measured at 20°C. It is a semisynthetic product derived from fermentation of the bacterium Streptomyces avermitilis.
Chemical structure.
https://stagingapi.mims.com/au/public/v2/images/fullchemgif/CSIVERME.gif Australian Approved Name (AAN): Ivermectin.
Chemical Names: 5-O-demethyl-22,23-dihydroavermectin A1a; 5-O-demethyl-25-de(1-methylpropyl)-25-(1-methylethyl)-22,23-dihydroavermectin A1a.
Molecular Formula and Molecular Weight: 22, 23-dihydroavermectin B1a C48H74O14 (R=C2H5) 875.10.
22, 23-dihydroavermectin B1b C47H72O14 (R=CH3) 861.07.
CAS number. 70288-86-7 (ivermectin), 71827-03-7 (ivermectin B1a), 70209-81-3 (ivermectin B1b).

7 Medicine Schedule (Poisons Standard)

S4 - Prescription Only Medicine.

Summary Table of Changes

https://stagingapi.mims.com/au/public/v2/images/fulltablegif/SOOLANST.gif